drugset / Trial / NCT00476099

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

NCT00476099

Phase 3 Completed 828 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.

Timeline

Start
2006-12
Primary completion
2008-08
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclomethasone Small molecule 100 ug Inhaled
Subject Budesonide Small molecule 200 ug Inhaled
Subject Formoterol Other / unclassified 6 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled